Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

42 trials with published results (33%)

Research Maturity

85 completed trials (66% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

3.9%

5 terminated out of 128 trials

Success Rate

94.4%

+7.9% vs benchmark

Late-Stage Pipeline

45%

57 trials in Phase 3/4

Results Transparency

49%

42 of 85 completed with results

Key Signals

42 with results94% success

Data Visualizations

Phase Distribution

115Total
Not Applicable (27)
Early P 1 (1)
P 1 (10)
P 2 (20)
P 3 (44)
P 4 (13)

Trial Status

Completed85
Recruiting17
Unknown10
Terminated5
Active Not Recruiting4
Enrolling By Invitation3

Trial Success Rate

94.4%

Benchmark: 86.5%

Based on 85 completed trials

Clinical Trials (128)

Showing 20 of 20 trials
NCT04987229Phase 3Enrolling By InvitationPrimary

Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

NCT05303064Phase 3Recruiting

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

NCT07172516Phase 3Recruiting

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

NCT07185815Phase 1Recruiting

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

NCT06560957Not ApplicableRecruiting

SYNCED - SYNChronized Eating in Bipolar Depression Study

NCT06273774Phase 1CompletedPrimary

A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)

NCT07540338Phase 1RecruitingPrimary

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

NCT07494305Phase 2RecruitingPrimary

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

NCT06696755Phase 2RecruitingPrimary

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

NCT04777357Phase 3Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

NCT07288320Phase 2RecruitingPrimary

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

NCT03484494Not ApplicableActive Not Recruiting

Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression

NCT05956340Not ApplicableCompleted

A Study of Spoken Language in Mania

NCT03919760Not ApplicableCompleted

Early Psychosis Intervention - Spreading Evidence-based Treatment

NCT07213466Phase 4RecruitingPrimary

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCT07217860Phase 3Enrolling By Invitation

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

NCT06804525Recruiting

LHC-CIDI-5 in Hong Kong

NCT05004896Phase 2Completed

Ketamine for Treatment-Resistant Bipolar Disorder

NCT05339074Phase 2Completed

Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression

NCT06256367CompletedPrimary

Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder

Scroll to load more

Research Network

Activity Timeline